LA VEGAS, NV / ACCESSWIRE / April 18, 2016 / Both pharmaceutical and biotech stocks had a rough year but technical indicators suggest that perhaps the bear market on these sectors is over. One company we are very bullish on is Endonovo Therapeutics, Inc. (ENDV).
Biotechs fell a full 40% from last summer's peak to their January lows. The recent bounce back, however, looks like a technical breakout by several biotech indexes. The iShares Nasdaq Biotechnology exchange-traded fund (ticker:ticker::IBB) completed a short-term double bottom last week with a huge surge through the top of that pattern. Momentum indicators and moving averages also pointed to improving conditions.
Since the day of the rally, the ETF has pulled back barely on lower volume, which indicates a pause in a larger movement and not a reversal. This appears to be an opportunity to buy the dip as it makes a technical test of the breakout.
This is why investors should immediately look into buying opportunities on volatile biotechs as the potential exists to yield huge profits!
Endonovo Therapeutics, Inc. (ENDV) began its breakout last week, hitting buy signals on practically every technical indicator there is: 10-8 Day Moving Hilo Channel; above the 20, 50, and 100 day Moving Averages; 20-50 day, 20-100 day, and 20-100 day MACD Oscillator; 40 and 60 day Commodity Channel Index; and the 50 Day Parabolic Time/Price Indicator. These indicators range from short to long term signals meaning whether you trade or invest, everything's pointing in the right direction for ENDV.
A few other biotechs that you can look at to take advantage of this biotech bull market are:
PTC Therapeutics, Inc. (PTCT) This company closed up just 43% on Friday. Keep a very close eye on this company!
Genocea Biosciences, Inc. (GNCA) Stock has basically doubled in the last month, we think it can go higher.
Second Sight Medical Products, Inc. (EYES) Stock has retreated as of late, could be a great buying opportunity.
Esperion Therapeutics, Inc. (ESPR) Stock is up about 25% over the last month, we see this stock continuing to climb.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $26,000 cash by a non-affiliate third party of ENDV.
SOURCE: ACR Communication, LLC